5 results match your criteria: "National Cancer Center EPOC[Affiliation]"
Lancet Healthy Longev
June 2024
Division of Cancer Immunotherapy, National Cancer Center EPOC, Kashiwa, Japan.
Lancet Healthy Longev
April 2024
The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
Mod Pathol
February 2024
Division of Molecular Pathology, National Cancer Center Research Institute, Tokyo, Japan; Division of Innovative Pathology and Laboratory Medicine, National Cancer Center EPOC, Tokyo, Japan. Electronic address:
Intrahepatic cholangiocarcinoma (iCCA) is an aggressive cancer composed of large-duct and small-duct types. Understanding the tumor immune microenvironment and its related vascular system is important for developing novel and efficient therapies. We focused on tertiary lymphoid structure (TLS) as a hallmark of antitumor immunity and investigated the clinicopathologic significance of TLSs and the influence of vascular microenvironment on TLS formation in iCCAs.
View Article and Find Full Text PDFAm J Surg Pathol
May 2023
Division of Molecular Pathology.
Acinar cell carcinoma (ACC) is a rare and highly malignant pancreatic tumor. Owing to histologic similarity, ACC is often difficult to distinguish from other solid medullary pancreatic tumors, particularly neuroendocrine neoplasm (NEN) and intraductal tubulopapillary neoplasm (ITPN). We aimed to identify new immunohistochemical markers commonly expressed in tumor cells with acinar cell differentiation and useful for both surgical and small biopsy specimens.
View Article and Find Full Text PDFObjective: To assess whether eldecalcitol, an active vitamin D analogue, can reduce the development of type 2 diabetes among adults with impaired glucose tolerance.
Design: Double blinded, multicentre, randomised, placebo controlled trial.
Setting: Three hospitals in Japan, between June 2013 and August 2019.